Instituut voor Neuropathische Pijn
English articles Research & Development Ibudilast, XT101 in neuropathic pain
| Ibudilast, XT101 in neuropathic pain |
The glial blocker XT101 demonstrated in the preclinical phase to be able to upregulates IL-10. It is developed by Xalud Therapeutics, Inc. Data on AV411 (ibudilast) has been presented by Paul Rolan, M.D., FRACP, Professor of Pharmacology, University of Adelaide, Australia, at the 10th International Conference on the Mechanisms and Treatment of Neuropathic Pain held in Salt Lake City, Utah, in 2007.
AV411 in neuropathic painSummary data were presented at the meeting demonstrating AV411 to be safe and well tolerated in a phase IIa study at doses up to 80 mg/day. The press release of the company stated: The data also indicated a favorable dose to blood plasma level relationship. Although in this preliminary efficacy trial there appears to be no difference in overall mean visual analog scale (VAS) scores between active and placebo arms, a pharmacokinetic assessment indicates an encouraging correlation between AV411 plasma levels and the number of patients that reported a decrease in pain scores as assessed by VAS. Additionally, there was a trend towards decreased opioid use that correlated with increased AV411 dose. These were the results from a a two-week, placebo-controlled, double-blinded study, primarily in patients suffering from diabetic neuropathy. The dose-escalating trial evaluated doses up to 80 mg/day. The trial was also designed to generate data to support larger clinical trials that Avigen started in 2008. October 2010, Jan M. Keppel Hesselink, MD, PhD |